Rana Zabad, MD

Dr. Rana K. ZabadAssociate Professor - Department of Neurological Sciences
Director – Multiple Sclerosis Program

Academic Office:  Clinic Practice Location: 
988440 Nebraska Medical Center
Omaha, NE 68198-8440
Phone: 402-559-5569
Fax: 402-559-3341
4242 Farnam Street, Suite 650
North Doctor's Tower
Omaha, NE 68131
Phone: 402-559-8600  

Administrative Assistant: Tova Safford     402-559-5569

American University of Beirut, Bachelor of Sciences (1988-1991)
St. Joseph University, Beirut, Lebanon, Medical Diploma (1991-1998)
Sinai-Grace Hospital, Wayne State University School of Medicine, Internship (1998-1999)
Wayne State University School of Medicine, Neurology Residency (1999-2002)
University of Calgary, Calgary, Alberta Canada, MS/Neuroimmunology Fellowship (2002-2005)

Hospital Appointments:
University of Nebraska Medical Center
VA Nebraska-Western Iowa Health Care System

Interests: Multiple Sclerosis/Neuroimmunology, neurosarcoidosis, CNS vasculitis, autoimmune diseases affecting the brain.

Biographical Sketch:
Dr. Rana K. Zabad is an Associate Professor and Director of the Multiple Sclerosis Program at the University of Nebraska Medical Center since October 2008. Dr. Zabad received her medical degree from St. Joseph University in Beirut, Lebanon, completed her internship and neurology residency at the Detroit Medical Center, Wayne State University School of Medicine in Detroit, Michigan. She further went for a fellowship in MS Neuroimmunology for 3 years at the University of Calgary in Calgary, Alberta, Canada under the mentorship of Drs. Luanne Metz and Wee Yong. Dr. Zabad is board certified by the American Board of Psychiatry and Neurology and a member of the American Academy of Neurology, the American Medical Association, National MS Society, Nebraska Chapter, the Consortium of MS centers, the United Leukodystrophy Foundation and the International Association of Health Care professionals. Dr. Zabad is a receiver of the Who’s Who award in Medicine in 2002.

Selected Publication:

  1. RK Zabad, LM Metz, TR Todoruk, Y Zhang, JR Mitchell, M Yeung, DG Patry RB Bell and V Wee Yong. The clinical response to minocycline in MS is accompanied by beneficial immune changes: a pilot study. Mult Scler 2007; 13(4):517-26.
  2. Y Zhang, RK Zabad, X Wei, LM Metz, MD Hill and J R Mitchell. Deep gray matter black T2 on 3 tesla magnetic resonance image correlates with disability in multiple sclerosis. Mult Scler 2007; 13(7):880-3.
  3. V Wee Yong, RK Zabad, S Agrawal, A Goncalves DaSilva, and LM Metz. Evaluation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators. J Neuro Sci, 2007; 259(1-2): 79-84.
  4. EK O’Ferrall, K Busche, P Dickhoff, RK Zabad and C Toth. A patient with bilateral sciatic neuropathies. Can J Neurol Sci 2007; 34(3):365-7.
  5. Giovannoni G, Barbarash O, Casset-Semanaz F, Jaber A, King J, Metz L, Pardo G, Simsarian J, Sørensen PS, Stubinski B; RNF Study Group. Immunogenicity and tolerability of an investigational formulation of interferon-β1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIB study in adults with multiple sclerosis. Clin Ther. 2007 Jun; 29(6):1128-45.
  6. O Khan, C Caon, A Tselis, R Zabad, M Reznar and R Lisak. Acute partial transverse myelitis with normal brain MRI: conversion to clinically definite multiple sclerosis after five years. J Neurol 2008; 255(1):89-93.
  7. JS Perumal, C Caon, Hreha S, R Zabad, A Tselis, R Lisak and O Khan. Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis. Eur J Neurol 2008; 15(7):677-80.
  8. Boster A, Caon C, Perumal J, Hreha S, Zabad R, Zak I, Tselis A, Lisak R, Khan O. Failure to develop multiple sclerosis in patients with neurologic symptoms without objective evidence. Multiple sclerosis 2008; 14(6):804-8.
  9. Gavin Giovannoni, Olga Barbarash, F. Casset Simanaz, John King, Luanne Metz, Lada Mitchell, Gabriel Pardo, James Simsarian, Per Soelberg Sörensen, Bettina Stubinski; on behalf of the RNF Study Group: Reduced immunogenicity with a new formulation of interferon beta-1a (Rebif®): 96-weeks results. Mult Scler. 2009 Feb; 15(2):219-28.
  10. Metz LM, Li D, Traboulsee A, Myles ML, Duquette P, Godin J, Constantin M, Yong VW; GA/minocycline study investigators. Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial. Mult Scler. 2009; 15(10):1183-94.
  11. Brown LN, Zhang Y, Mitchell JR, Zabad RK, Metz LM: Corpus callosum volume an
    interhemispheric transfer in multiple sclerosis. Canadian Journal of Neurosciences December 2010.